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Perigraft Seroma after Extra-anatomic Bypass:
Case Series and Review of the LiteratureQ1
Q10 Daniele Bissacco,1,2 Maurizio Domanin,1,2 Silvia Romagnoli,1 and Livio Gabrielli,1,2 Milan,
Italy
Background: Extra-anatomic bypass (EAB) remains a viable alternative for lower limb revas-
cularization if aorto-bifemoral bypass and endovascular therapy are contraindicated. Among
EAB, periprosthetic seroma (PS) occurs in about 4% of cases. Diagnostic and therapeutic man-
agement, as well as standardized treatment paradigm, are still not well defined. The aim of this
study is to report 5 PS cases in EAB and to review literature about similar cases.
Methods: We retrospectively reviewed EAB performed during the period 2002e2015. Among
these, we described PS cases. A similar description for all cases found in the literature through
research on the major international databases (PubMed, Scopus, EMBASE) was made.
Results: During the study period, 797 bypassesd528 (66.3%) anatomical and 269 (33.7%)
extra-anatomicaldwere performed. Among the latter, 169 femoro-femoral (FF), 20 axillo-
femoral (AXF), 22 axillo-bifemoral (AxBF), and 58 aortouni-iliac endoprosthesis (AUI) + FF
bypasses were performed. Five cases (1.86%) of PS in EAB population were detected: 3 after
AxBF and 2 after AUI + FF. Although we initially preferred percutaneous drainage, a surgical
choice with graft explant and replacement were imposed by the high recurrence rate. Literature
analysis identified 19 additional cases (11 after AxBF, 7 after AXF and after AUI + 1 FF).
Conclusions: Our case series and the literature confirm that the most widely used therapy is
the surgical drainage with primary or secondary replacement of the graft of a different material.
Percutaneous drainage has proved ineffective because not conclusive and potential to increase
risk of graft infectionQ4 . Careful follow-up, even years after surgery, remains necessary for diag-
nosis of this complication, to document the possible PS and prevent potential infection.
INTRODUCTION
Extra-anatomic bypass (EAB) grafts, that is, axillo-
femoral (AxF), axillo-bifemoral (AxBF), or
femoro-femoral (FF), are excellent alternatives for
revascularization of aorto-iliac occlusive disease in
high-risk patients (HRP).1e3 Moreover, the
aortouni-iliac (AUI) repair with FF bypass is the
ideal solution in case of endovascular aneurysm
repair (EVAR) of an abdominal aortic aneurysm
(AAA) with poor iliac axes, showing good long-
term patency rates.4
However, they can be burdened with several
complications that all bypass grafts have in com-
mon, such as thrombosis, infections, pseudoaneur-
ysms, and so on. Among these, perigraft seroma
(PS Q5) is a peculiar complication of EAB grafts that
consists in persistent sterile fluid that collects
around the graft with pseudocapsules formation.
The real prevalence of PS is difficult to estimate,
considering its sporadic nature and late onset. Its
prevalence has been reported between 0.48% and
4.2%.5e8
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Etiology and natural history of PS have not yet
been clearly clarified, nor therapeutic indications.
Several hypotheses have been advanced to explain
the serum accumulation after vascular graft
implants, including both graft- or patient-related
factors, although the pathogenesis appears to be
multifactorial.
Clinical presentation includes a nonpulsatile,
nontender swelling along the course of the bypass.
Usually, there is no discomfort at rest, but pain is
sometimes caused by palpation or by coughing,
particularly when PS occurs after FF bypass. Some-
times a slight erythema of the overlying skin can
be observed.9,10 Because this collection is asymp-
tomatic in most cases and the graft remains patent,
the patient usually shows up when the PS has
achieved relevant dimensions, feeling anxious and
afraid about progressive growth of the mass along
the graft in a subcutaneous location.
Diagnosis is primarily clinical: patient’s history
together with physical examination is mandatory
to steer the surgeon in diagnostic and therapeutic
choices. The time interval of PS development and
the presence of fever or other systemic symptoms
must be always investigated. Blood tests including
complete blood count, coagulation, C-reactive pro-
tein, and erythrocyte sedimentation rate are
required to exclude infection.
Doppler ultrasound (DUS) is the first choice
instrumental investigation to evaluate graft patency
and PS size. Computed tomographic angiography
(CTA) should be considered only as a second-level
test to assess PS extension and to exclude anasto-
motic pseudoaneurysms.
As for the previous issues, ideal treatment has not
yet been defined and indications range from watch-
ful waiting approach to complete removal of EAB
graft and its substitution with a graft of different ma-
terial. We present a case series of PS after AxBF
bypass and AUI endograft + FF crossover bypasses,
together with a literature review of similar cases,
to define clinical presentation, therapeutic decision




A 75-year-old woman with a history of chronic
obstructive pulmonary disease, hypertension, and
myocardial infarction underwent polytetrafluoro-
ethylene (PTFE) AxBF bypass graft due to an
aorto-bifemoral bypass graft thrombosis, 15 months
after surgery for an AAA. Duplex ultrasonography
scan (DUS Q6), performed 8 months after EAB surgery,
showed graft’s patency and a 40 250mmdiameter
capsulated PS along the EAB graft left branch.
Seromawas initially drained by percutaneous punc-
ture. Because of its rapid recurrence, 3 months later
the patient underwent a left branch excision and
replacement with a Dacron graft. After 17 months
from replacement, no periprosthetic collections are
detected by DUS. The patient has always remained
asymptomatic.
Case 2
A 70-year-old woman showed an asymptomatic
swelling in correspondence to Dacron AxBF bypass
graft, performed 2 years before for aorto-enteric fis-
tula (AEF) and aorto-bifemoral bypass graft infection.
Blood tests showed no abnormalities. CT-scan with
contrast media (CTA) revealed periprosthetic collec-
tion along the whole bypass course, more visible in
the suprapubic tract, with a maximum diameter of
128 mm. At first, the patient underwent PS surgical
drainage and muscular wrapping of the graft in the
axillary and suprapubic region. A second surgical
drainage with total PS capsule removal till the breast
region was performed 15 months later because of
recurrence. Capsule microscopic examination
revealed mature connective tissue with congested
and swollen vessels, focal extravasation bleeding,
and acute inflammation. A new relapse complicated
by Staphylococcus aureus spp. graft infection required
a complete EAB graft replacement with a new PTFE
graft. Twenty-two months later, no PS recurrence
was observed by CDUS Q7examination.
Case 3
Our recent publication5 described a 75-year-old
man with a tender and pulseless suprapubic mass,
painful when coughing. The patient had a history
of Leriche’s syndrome treated by right Dacron
AxBF bypass performed 2 years earlier. A CT-scan
showed the presence of a 121-mm diameter giant
PS, extending from the bifurcation to the anasto-
mosis of the receiving limb. The bypass was patent
and no visible signs of periprosthetic infection
were demonstrated. The patient subsequently un-
derwent surgical drainage of the mass content,
removing the capsule and the affected graft portion,
with reconstruction of the contralateral bypass
branch in expanded polytetrafluoroethylene
(ePTFE 8 mm) graft. PS contained serous and sterile
fluids. Fibrous and adipose tissue with vascular ecta-
sia, extravasations, and chronic inflammation were
found in the pseudocapsule specimen. Six months
later, a DUS revealed a modest, periprosthetic,
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asymptomatic PS recurrence. The patient has not
yet undergone reoperation due to comorbidities.
Case 4
A 70-year-old man suffering from a 6.7-cm AAA
underwent EVAR with left AUI stent graft (Zenith
Flex; Cook Medical, Bloomington, IN) and left to
right Dacron knitted FF crossover bypass graft.
Twelve months after surgery, DUS revealed a
57  31 mm right FF anastomosis PS. First, the pa-
tient underwent surgical drainage and muscle flap
coverage of the graft. A second surgical drainage
was performed 4 months later because of recur-
rences. Eight months later, an Staphylococcus aureus
spp. prosthetic infection occurred and the FF cross-
over bypass graft was replaced with an 8-mm
silver-coated Dacron graft. Intraoperative findings
showed a well healed left anastomoses, whereas
the right one appeared unstuck from surrounding
tissues. The DUS performed 1 year after surgery
showed extra-anatomic graft patency with no new
signs of periprosthetic collections.
Case 5
An 84-year old man with a clinical history of hyper-
tension, chronic lymphocytic leukemia, and chronic
occlusion of the right common iliac artery under-
went EVAR for an 8.25 cm AAA. A left AUI stent
graft (Endurant II; Medtronic, Santa Rosa, CA)
together with a left to right FF PTFE bypass graft
were performed.
Approximately 1 month after EVAR, he came
back to our department because of a small, painless
mass along the FF bypass, particularly close to the
left section. Conservative therapy was useless and
3 weeks later percutaneous aspiration was per-
formed, with complete recovery. DUS performed 6
months later revealed graft patency and mild
asymptomatic recurrence.
METHODS
We retrospectively investigated all EAB grafts per-
formed at our division between January 1, 2002
and December 31, 2015 and detected, among these,
all cases of PS, referring to the definition offered by
Blumenberg: ‘‘a collection of clear, sterile fluid,
confined within at nonsecretory fibrous pseudo-
membrane surrounding a vascular graft.’’10
A review of the current literature on main inter-
national scientific medical databases (PubMed,
EMBASE, Scopus) was simultaneously conducted,
using as keywords the terms ‘‘perigraft seroma,’’
‘‘perigraft hygroma,’’ ‘‘extra-anatomical bypass
graft,’’ and ‘‘vascular surgery complication,’’ with
no language or time filters. We took into account
exclusively cases of PS following EABs (AxBF,
AxF, or FF). Articles describing patient and bypass
characteristics, first surgical procedure, diagnostic
process, therapeutic methods, and clinical outcomes
were included in the analysis.
RESULTS
During the study period, 797 lower limb bypasses
have been performed in our division. Among these,
528 (66.3%) anatomic and 269 (33.7%) extra-
anatomic (among these 169 FF, 20 AxF, 22 AxBF,
and 58 AUI + FF) were realized. Five PS (1.86%)
among EAB population (3 after AxBF and 2 after
AUI + FF) occurred. One case occurred after a
femoro-popliteal bypass was excluded from the
analysis. Table I shows own case series characteris-
tics and outcomes.
Patients involved were 3 men and 2 women with
an average age of 75 ± 5 years. PS diameters at diag-
nosis were between 57 and 250 mm. Graft material
implicated was Dacron knitted in 3 cases and PTFE
in those remaining. The graft was patent in all
patients at the time of PS diagnosis.
Conservative approach with percutaneous
drainage was initially performed in 2 cases, while
surgical drainage without graft removal was chosen
for 3 patients. In 4 cases, because of the high recur-
rence rate, patients had been subjected to a subse-
quent invasive approach with surgical drainage
and affected graft substitution. The replacement
was performed in all cases with grafts of different
materials. The liquid collected was always clear
and sterile. Two pseudocapsules were analyzed
with no interesting results. Graft’s muscular
coverage was performed in just one case although
being ineffective for recurrence of PS.
Literature review showed 20 additional cases of
PS after extra-anatomical bypass (Table II): 15
men, 1 woman, and 4 cases not specified.9e20 Pa-
tients’ average age reported was 68 ± 11 years (16
cases analyzed). Indications for primary surgery
were aortic or aorto-iliac occlusion (7 cases),
aorto-bifemoral ABF bypass (2 cases) or AAA infec-
tion (1 case), and lower limb revascularization or
AAA correction in HRP (4 cases). In one case, the
procedure was performed for AEF, in another one
for noncomplicated AAA, and in a third case for
contralateral AxBF thrombosis. Seven AxFs (3 right
AxFs, 3 left AxFs, 1 not specified), 11 AxBFs, and 1
AUI endograft + FF bypass graft were described.
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The prosthetic material used was Dacron (10 cases)
or PTFE (9 cases). In one case, no information
regarding graft material was specified. The time in-
terval between graft insertion and manifestation of
seroma was quite variable (median 3 months; inter-
quartile range 2e16 months).
All studies published reported patency of the EAB
at the time of PS diagnosis. Themaximum diameters
of PS were declared only in 3 cases. In half of the
reported cases symptoms were described and most
patients were asymptomatic.
Therapy was conservative in 4 cases; local
compression (1 case), fibrin sealing technique
(1 case), percutaneous drainage (2 cases), surgical
drainage (2 cases), multiple drainages followed by
graft replacement and seroma removal (7 cases),
and primary surgical graft removal (2 cases). In
one case, microfibrillar collagen (MFC) was injected
into the seroma after multiple surgical drainage and
graft replacement. The drained clear serous fluid
was sterile in all cases. When the surgical option
was preferred to treat PS, all patients were submitted
to graft removal and replacement, with a different
prosthetic material (7 cases from Dacron to ePTFE,
3 cases from ePTFE to Dacron).
The follow-up period of the analyzed studies was
rather variable (from a few days up to 4 years) and
there were no enlargements or recurrence, with
the exception of one case where continuous percu-
taneous drainage was necessary to control rapid
recurrence.
DISCUSSION
The real prevalence of PS is difficult to estimate and
data collected from literature refer to monocentric
case series or surveys and date at least 25 years
ago.6e8 Current literature does not offer review
regarding PS development after AUI and FF bypass.
In our experience, the incidence of PS after EABs
was lower compared with the one reported in the
literature although it remains still uncertain, for
the reasons previously described.
The etiology of PS remains still unidentified.
Several hypotheses have been advanced to explain
the serum accumulation after vascular graft implants,
including both graft- or patient-related factors,
although the pathogenesis appears to be multifacto-
rial. The most likely theories include host versus graft
reaction,9 pseudoinfection,21 immunoallergic
reaction,6,22 ultrafiltration,8,10 anomalous graft incor-
poration,23e26 failure of wound repair process,26
fibroblast transformation7 with fluid exudation by
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Table II. Current literature results





diagnosis Symptoms Therapy Outcome


















Blumenberg, 198510 4 Male 65 AxF(R) for iliac
occlusion in HRP





5 Male 86 AxF(L) for iliac and
femoral occlusion
PTFE NS 1 month NS Multiple drainage Progressive
diminution at
9 months
6 Male 63 AxBF for infected
AAA
Dacron NS 3 years Asx None Progressive
diminution at
2 years











patency at 2 years








9 Male 63 AxBF for aortic
occlusion











IIzima, 199113 11 Male 70 AxF(R) for PAD after
contralateral
amputation Q9



















































































































































































































































































































































































diagnosis Symptoms Therapy Outcome
Inari, 200514 12 Male 77 AxBF for aortic
occlusion









Dacron NS 9 days Asx None No postoperative
recurrence
14 Male 77 AxBF in HRP Dacron NS 26 days NS Local compression NS
Zanow, 201015 15 NS NS AxF ePTFE NS 32 months NS FST No recurrence.
Patient died
28 months later
Fukunaga, 201316 16 Male 81 AxBF for ABF graft
infection
ePTFE NS NS Asx Surgical drainage No recurrence at
discharge
Ho, 201317 17 Male 79 AxBF for infected ABF
Dacron graft




died 4 years later




Gazi, 201519 19 Male 54 AxBF for aortic
thrombosis in HRP





Kunimoto, 201520 20 Male 75 AxBF(L) for AxBF(R)
thrombosis after
mycotic AAA





















































































































































































































































































































































































There is no consensus regarding the preferential use
of Dacron or PTFE to prevent PS formation.
Advances in prosthetic materials manufacture
could have contributed to reducing the occurrence
of PS during the years. On account of the fact that
PS also occurred after subfascial graft coverage, we
assume that graft material should be involved in
the process of fluid collection more than the peri-
prosthetic environment. Moreover, partial incorpo-
ration of the graft at the anastomotic site was also
observed in our series (cases 4 and 5).
Therapeutic indications are not yet well defined.
The treatment can be conservative, mini-invasive,
or surgical, although when necessary, graft replace-
ment is often needed.
Watchful waiting with DUS follow-up and
compressive therapy is preferred inmild and asymp-
tomatic PS. Zanow recommends conservative
approach for seromas < 2 cm in diameter, without
anastomotic region involvement.15
If invasive treatment is needed, the therapy aims
to remove the swollen mass, to decrease symptoms
associated, to minimize PS recurrence rate, and to
avoid bypass occlusion and/or infection. Although
some authors support a primary mini-invasive
approach with percutaneous drainage,9,13,14,17,18
this is not recommended considering its high recur-
rence rates and risks of seroma and, therefore, graft
infection. In our series, in fact, we have performed
PS drainage (with DUS control) mainly to delay sur-
gery in HRP with larger PS.
When needed, graft replacement with one of
different material appears to be the most definitive
treatment and can involve a decrease in graft
permeability and periprosthetic reaction to foreign
body. There is no difference in Dacron to ePTFE
replacement or vice versa. Pseudocapsule’s removal
and surgical drainage alone should be avoided, since
not curative and causing a high rate of infection.10
Replacement with homograft28 or native vein,29
saphenous vein wrapping,30 interposition of covered
stents,31 and MFC injection into the periprosthetic
space12 are alternative therapies tested in a very
limited number of cases. Plasmapheresis24 and intra-
venous fibrinogen administration32 were performed
to wash out hypothetical serum factors regarded as
likely to modify the normal graft permeability.
A fundamental issue in PSmanagement is patient
counseling. It is extremely important to reassure
these patients on the kindness of such complication.
Even so, these patients often appear very apprehen-
sive and continuously requesting explanations on
the nature of the growing mass, particularly when
a complicated past medical history exists.
Treatment decision-making process should always
take into account important issues such as PS dimen-
sion and growth rate, symptomatology, and patient’s
condition. Due to the lack of dimensions’ data in the
literature, absolute treatment recommendations
remain aleatory and thereby therapy is often
patient-tailored. Our cases have larger diameters if
comparedwith those reported in the literature. There-
fore, we assume that the greater the size of PS, the
greater is the indication for surgical replacement ther-
apy, although there are no specific cutoff values. A
complete removal of the pseudocapsule together
with graftmaterial replacement of the affected portion
is mandatory. Histopathological analysis of perigraft
fluid, pseudocapsule, and explanted graft specimen
may be avoided if no signs of infection are detected.
CONCLUSION
PS is a rare complication that can occur even after
several years from graft placement. Triggering factors
are not yet clarified, although graft-related and
patient-related elements may play a role in peripros-
thetic fluid’s accumulation. Several therapeutic op-
tions have been proposed, but none have reached
satisfactory results in a sufficient number of cases.
In our experience, both conservative treatment and
percutaneous/surgical drainage proved to be futile,
due to a higher risk of prosthesis infection and PS
recurrence. Graft removal and replacement with
another material had the best results, although not
yet optimal. Anyways, very few and selected patients
beneficiate from surgery which, on the basis of our
experience, is worthy only in case of greater swelling
and/or growing masses with reported inability to
walk, discomfort, or pain. Regarding EABs, we
recommend a long-term follow-up after surgery, to
assess graft patency and any periprosthetic fluid
collection worthy of further investigation.
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